Labs and Production Sites
Sinotau has many radiopharmaceutical labs and production sites among Beijing, Shanghai, Sichuan, Guangdong, Jiangsu to accelerate our robust capabilities of R&D and production and to support the discovery, clinical translation, production and supply of radiopharmaceuticals across the major markets nationwide.
Labs
Beijing: Central Laboratory & New Drug Discovery Center
- Innovative radiopharmaceutical R&D center covering an area of 2800 square meters，with radiological and non-radiological laboratories.
- Establised an early-stage R&D platform for radiopharmaceuticals based on antibodies or peptides, which strongly supports ealy discovery and clinical translation.
- Equipped with a full range of innovative early-stage antibody research and development team, equipments, and capabilities.
Shanghai: New Drug Discovery Center
- Innovative radiopharmaceutical early R&D center covering an area of 1500 square meters.
- Covering early target validation, small molecule- and peptide- precursor discovery, and early CMC research, etc.
Production Sites
Wuxi, Jiangsu
- A class B qualified production site with a building area of 10699 square meters, which mainly produce diagnostic radiopharmaceuticals with accelerators, and cover the Yangtze River Delta region.
- Has obtained “Radiation Safety License”, possessing the capability for research and production.
- Extensive experience in technology transfer, covering clinical samples and commercial product supply.
Zhongshan, Guangdong
- A class B qualified production site covering specializing in radiopharmaceuticals, with a building area of 11,624 square meters.
- Possessing the necessary qualifications for the production and operation of radiopharmaceuticals, the site has established a comprehensive radiation safety management system, as well as pharmaceutical production and quality management systems.
- Equipped with cyclotrons produced a wide range of solid-target based radionuclides with stable and continuously optimized capacity.
- Experienced in technology transfer, covering the supply of clinical samples and commercialized products, serving the Pearl River Delta, Guangdong-Hong Kong-Macao Greater Bay Area, etc.
Mianyang, Sichuan
- A Class A qualified production site mainly producing therapeutic radiopharmaceuticals, which coveries a building area of 21549 square meters.
- By 2024, it is planned to officially produce, becoming the most intelligent and comprehensively planned therapeutic radiopharmaceutical production site in China.
- Has engaged in deep strategic cooperation with reactors to achieve a stable supply of commonly used medical isotopes.
- Has completed the construction of numerous radiopharmaceutical production lines, with distribution spanning major regions in China and some parts of Asia.
